Home / Recalls / Allergan Sales, LLC / D-1056-2019

D-1056-2019 Class II Terminated

Recalled by Allergan Sales, LLC — Waco, TX

Recall Details

Product Type
Drugs
Report Date
April 3, 2019
Initiation Date
March 19, 2019
Termination Date
April 29, 2020
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
72 bottles

Product Description

Combigan (brimonidine tartrate/timolol maleate ophthalmic solution) 0.2%/0.5% 5 mL bottles, Rx only, Allergan, Inc. Irvine, CA 92612 U.S.A. NDC 0023-9211-05

Reason for Recall

cGMP Deviations

Distribution Pattern

TN only

Code Information

Lot#: 99946 Exp. January 16, 2021

Other recalls by Allergan Sales, LLC

  • Z-1694-2024 Class II — Keller Funnel 2, REF: HA-001, STERILEEO, Rx Only, (March 14, 2024)
  • D-0078-2018 Class III — Lumigan (bimatoprost ophthalmic solution) 0.01%, 2.5 mL bottle, Rx only, Allerg (October 19, 2017)
  • D-0077-2018 Class III — Combigan (brimonidine tartrate/timolol maleate ophthalmic solution) 0.2%/0.5%, R (October 19, 2017)
  • D-0929-2017 Class II — Blephamide (sulfacetamide sodium and prednisolone acetate ophthalmic ointment, U (May 1, 2017)
  • D-0667-2017 Class III — Lumigan (bimatoprost ophthalmic solution) 0.01%, 7.5 mL bottle, Rx only, Allerga (March 16, 2017)
  • D-0099-2017 Class II — TAZORAC (tazarotene) Gel 0.05%, Rx only, For Dermatologic Use Only, Not for Opht (June 30, 2016)
  • D-0100-2017 Class II — TAZORAC (tazarotene) Gel 0.05%, Rx only, packaged in 15 x 3.5 g professional sam (June 30, 2016)
  • D-1064-2016 Class II — Tazorac (tazarotene) Gel 0.05%, Rx only, packaged in a) 30g (NDC 0023-8335-03) a (May 10, 2016)
  • D-1065-2016 Class II — Tazorac (tazarotene) Gel 0.05%, 15 x 3.5g, sample packs, Allergan Inc, Irvine, (May 10, 2016)
  • D-1819-2015 Class II — FML (fluorometholone ophthalmic ointment) 0.1%, 3.5 g tube, Rx only, Allergan, I (August 24, 2015)